Cancer Genetics Inc (NASDAQ:CGIX) target price raised to $6.00, issued a report today by HC Wainwright
- Updated: September 26, 2016
Cancer Genetics Inc (NASDAQ:CGIX) had its target price raised to $6.00 by HC Wainwright in a report released 9/27/2016. The new target price indicates a possible upside of 2.41% based on the company's last stock close price.
Previously on 9/26/2016, Rodman & Renshaw reported about Cancer Genetics Inc (NASDAQ:CGIX) raised the target price from $0.00 to $6.00. At the time, this indicated a possible upside of 2.41%.
Yesterday Cancer Genetics Inc (NASDAQ:CGIX) traded 5.11% higher at $1.76. The company’s 50-day moving average is $2.07 and its 200-day moving average is $2.26. The last stock close price is down -18.13% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 350,314 shares of the stock were exchanged, up from an average trading volume of 101,872
See Chart Below
With a total market value of $0, Cancer Genetics Inc has with a one year low of $1.72 and a one year high of $8.99 .
A total of 3 equity analysts have released a research note on CGIX. Two equity analysts rating the company a strong buy, one equity analyst rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $8.42.
More About Cancer Genetics Inc (NASDAQ:CGIX)
Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It has a range of disease-focused oncology testing portfolio. Its molecular- and biomarker-based diagnostic services are provided for three sectors: cancer centers and hospitals, biotechnology and biopharmaceutical companies, and the research community.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.